ASH Flash 2: Initial Data Show Responses are Maintained After Dose Reduction

From the American Society of Hematology:

3135 Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: 

Conclusions: Ponatinib continues to exhibit deep and durable responses in heavily pretreated pts with longer follow-up, particularly CP-CML. A dose reduction strategy was implemented in response to the observation of ATEs.  Initial data show responses are maintained after dose reduction; longer follow-up is needed to understand impact on safety.  A dose-ranging trial of ponatinib in refractory CML to evaluate benefit/risk is being planned.